RS55929B1 - Kristalni oblici 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida - Google Patents

Kristalni oblici 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida

Info

Publication number
RS55929B1
RS55929B1 RS20170384A RSP20170384A RS55929B1 RS 55929 B1 RS55929 B1 RS 55929B1 RS 20170384 A RS20170384 A RS 20170384A RS P20170384 A RSP20170384 A RS P20170384A RS 55929 B1 RS55929 B1 RS 55929B1
Authority
RS
Serbia
Prior art keywords
methyl
ylamino
benzamide
imidazol
pyrimidin
Prior art date
Application number
RS20170384A
Other languages
English (en)
Inventor
Paul W Manley
Wen-Chung Shieh
Paul Allen Sutton
Piotr H Karpinski
Raeann Wu
Stéphanie Monnier
Jörg Brozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS55929(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of RS55929B1 publication Critical patent/RS55929B1/sr
Publication of RS55929B2 publication Critical patent/RS55929B2/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20170384A 2005-07-20 2006-07-18 Kristalni oblici 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida RS55929B2 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70140505P 2005-07-20 2005-07-20
US71621405P 2005-09-12 2005-09-12
EP10173956.3A EP2284167B2 (en) 2005-07-20 2006-07-18 Crystalline form of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Publications (2)

Publication Number Publication Date
RS55929B1 true RS55929B1 (sr) 2017-09-29
RS55929B2 RS55929B2 (sr) 2020-12-31

Family

ID=37451227

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20170384A RS55929B2 (sr) 2005-07-20 2006-07-18 Kristalni oblici 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida

Country Status (43)

Country Link
US (4) US8343984B2 (sr)
EP (5) EP2535337B1 (sr)
JP (3) JP5289948B2 (sr)
KR (3) KR101651288B1 (sr)
CN (2) CN102358736A (sr)
AR (1) AR054846A1 (sr)
AU (3) AU2006276204A1 (sr)
BR (1) BRPI0613615B1 (sr)
CA (1) CA2614334C (sr)
CR (1) CR9657A (sr)
CU (1) CU23916B1 (sr)
CY (2) CY1113076T1 (sr)
DK (2) DK2284167T4 (sr)
EA (2) EA016856B1 (sr)
EC (1) ECSP088119A (sr)
ES (3) ES2623608T5 (sr)
GE (1) GEP20115302B (sr)
GT (1) GT200600315A (sr)
HK (1) HK1116783A1 (sr)
HN (1) HN2008000311A (sr)
HR (2) HRP20120573T1 (sr)
HU (1) HUE031791T2 (sr)
IL (2) IL188189A0 (sr)
JO (1) JO3308B1 (sr)
LT (1) LT2284167T (sr)
MA (1) MA29626B1 (sr)
MX (1) MX2008000899A (sr)
MY (1) MY148554A (sr)
NI (1) NI200800017A (sr)
NO (1) NO341930B1 (sr)
NZ (1) NZ564409A (sr)
PE (1) PE20070214A1 (sr)
PH (1) PH12013501590A1 (sr)
PL (2) PL1912973T3 (sr)
PT (2) PT1912973E (sr)
RS (1) RS55929B2 (sr)
SG (1) SG163620A1 (sr)
SI (2) SI1912973T1 (sr)
SM (1) SMP200800011B (sr)
TN (1) TNSN08029A1 (sr)
TW (1) TWI406661B (sr)
UA (1) UA94234C2 (sr)
WO (1) WO2007015870A2 (sr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
KR20090031855A (ko) * 2006-04-07 2009-03-30 노파르티스 아게 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과조합된 ｃ-ｓｒｃ 억제제의 용도
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
JP2011507880A (ja) 2007-12-21 2011-03-10 ノバルティス アーゲー 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤
US20100016590A1 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
KR101251726B1 (ko) 2008-11-05 2013-04-05 테바 파마슈티컬 인더스트리즈 리미티드 닐로티닙 ＨＣｌ 결정형
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
BRPI1013366A2 (pt) 2009-03-06 2016-03-29 Novartis Ag uso de derivados de pirimidilaminobenzamida para o tratamento de distúrbios mediados pela quinase contendo zíper de leucina e quinase contendo motivo alfa estéril (zak).
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
MX2012004709A (es) 2009-10-23 2012-05-23 Novartis Ag Metodo para el tratamiento de transtornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r.
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2010KO00035A (sr) * 2010-01-15 2016-09-02
JP2013525296A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー 内分泌療法抵抗性乳癌の処置
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
US8937082B2 (en) 2010-06-21 2015-01-20 Teva Pharmaceutical Industries Ltd. Nilotinib salts and crystalline forms thereof
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
US8703788B2 (en) * 2010-11-26 2014-04-22 Bandi Parthasaradhi Reddy Polymorph of nilotinib hydrochloride
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
CA2853095A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013074432A1 (en) 2011-11-14 2013-05-23 Novartis Ag Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
EP2626355B1 (en) * 2012-02-09 2016-02-03 Natco Pharma Limited Process for the preparation of nilotinib hydrochloride
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
IN2014DN10801A (sr) 2012-07-11 2015-09-04 Novartis Ag
CA2888002A1 (en) 2012-10-15 2014-04-24 Apotex Inc. Solid forms of nilotinib hydrochloride
CA2887540A1 (en) * 2012-10-19 2014-04-24 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
SG11201505680RA (en) * 2013-02-21 2015-09-29 Pfizer Solid forms of a selective cdk4/6 inhibitor
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
EP2989090A4 (en) * 2013-04-24 2017-01-18 Dr. Reddy's Laboratories Ltd. Polymorphic forms of nilotinib hydrochloride
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
US9926296B2 (en) 2014-08-08 2018-03-27 Dr. Reddy's Laboratories Limited Process for the preparation of polymorphic forms of nilotinib hydrochloride
MX2017004770A (es) * 2014-10-16 2017-07-26 Apotex Inc Formas solidas del clorhidrato de nilotinib.
EP3408264B1 (en) 2016-01-26 2020-03-11 Farma GRS, d.o.o. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
EP3430004B1 (en) 2016-03-14 2020-07-15 Pliva Hrvatska D.O.O. Solid state forms of nilotinib salts
CN106496193A (zh) * 2016-09-13 2017-03-15 福格森（武汉）生物科技股份有限公司 一种高纯度尼罗替尼的制备方法
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CN116808044A (zh) 2018-06-15 2023-09-29 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法
WO2020095187A1 (en) * 2018-11-05 2020-05-14 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
CA3181361A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
EP4355306A1 (en) 2021-06-19 2024-04-24 Helm AG Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
CN116102540A (zh) * 2023-01-05 2023-05-12 浙江工业大学 两种尼洛替尼游离碱新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701406A (en) 1901-07-16 1902-06-03 Thomas K Jones Cut-off-valve mechanism.
US701405A (en) 1902-02-17 1902-06-03 Archibald White Maconochie Ejecting device for stamping-machines.
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
NZ547195A (en) * 2003-11-18 2010-06-25 Novartis Ag Inhibitors of the mutant form of kit
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) † 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Also Published As

Publication number Publication date
TNSN08029A1 (en) 2009-07-14
MY148554A (en) 2013-04-30
DK1912973T3 (da) 2012-07-23
US8829015B2 (en) 2014-09-09
GT200600315A (es) 2007-03-19
SI1912973T1 (sl) 2012-08-31
EP2535337B1 (en) 2017-08-23
EP2284167B2 (en) 2019-11-27
EP2284167A2 (en) 2011-02-16
BRPI0613615B1 (pt) 2022-02-08
US20080269269A1 (en) 2008-10-30
EP2543665A3 (en) 2013-05-29
PT2284167T (pt) 2017-05-15
JP2014221831A (ja) 2014-11-27
NO20080820L (no) 2008-04-15
HRP20170634T4 (hr) 2020-02-07
ES2623608T3 (es) 2017-07-11
AU2012201453C1 (en) 2024-05-23
CN103804356A (zh) 2014-05-21
CR9657A (es) 2008-04-16
DK2284167T4 (da) 2020-03-02
EP2284168A2 (en) 2011-02-16
PT1912973E (pt) 2012-09-03
JO3308B1 (ar) 2018-09-16
HRP20170634T1 (hr) 2017-06-30
CU20080006A7 (es) 2011-02-24
TW200740793A (en) 2007-11-01
NO341930B1 (no) 2018-02-19
HRP20120573T1 (hr) 2012-08-31
PE20070214A1 (es) 2007-04-02
EP2284167A3 (en) 2011-03-02
ECSP088119A (es) 2008-02-20
AU2012201453B2 (en) 2013-09-05
AU2011202047A1 (en) 2011-05-26
RS55929B2 (sr) 2020-12-31
IL214659A0 (en) 2011-09-27
MX2008000899A (es) 2008-03-18
US20130023548A1 (en) 2013-01-24
HN2008000311A (es) 2011-01-24
UA94234C2 (uk) 2011-04-26
HUE031791T2 (en) 2017-08-28
SMAP200800011A (it) 2008-02-27
PL2284167T5 (pl) 2020-07-27
SG163620A1 (en) 2010-08-30
GEP20115302B (en) 2011-10-10
EA201000145A1 (ru) 2010-06-30
ES2623608T5 (es) 2020-06-18
EP2284167B1 (en) 2017-02-01
PL2284167T3 (pl) 2017-07-31
AU2006276204A1 (en) 2007-02-08
EA200800201A1 (ru) 2008-06-30
CA2614334A1 (en) 2007-02-08
ES2648288T3 (es) 2017-12-29
PH12013501590A1 (en) 2015-09-21
NZ564409A (en) 2011-07-29
CY1119624T1 (el) 2018-04-04
EA016856B1 (ru) 2012-08-30
JP5798101B2 (ja) 2015-10-21
WO2007015870A3 (en) 2007-06-07
JP2013018789A (ja) 2013-01-31
CY1113076T1 (el) 2016-04-13
US8343984B2 (en) 2013-01-01
EA013464B1 (ru) 2010-04-30
KR20080027853A (ko) 2008-03-28
HK1116783A1 (sr) 2009-01-02
KR20130085444A (ko) 2013-07-29
WO2007015870A2 (en) 2007-02-08
EP2535337A1 (en) 2012-12-19
PL1912973T3 (pl) 2012-09-28
AR054846A1 (es) 2007-07-18
SMP200800011B (it) 2008-02-27
KR20130077915A (ko) 2013-07-09
JP2009502795A (ja) 2009-01-29
KR101651288B1 (ko) 2016-08-25
SI2284167T2 (sl) 2020-03-31
AU2012201453A1 (en) 2012-04-05
MA29626B1 (fr) 2008-07-01
US20130165465A1 (en) 2013-06-27
SI2284167T1 (sl) 2017-05-31
JP5289948B2 (ja) 2013-09-11
US20140343087A1 (en) 2014-11-20
US8415363B2 (en) 2013-04-09
CU23916B1 (es) 2013-07-31
EP2543665A2 (en) 2013-01-09
LT2284167T (lt) 2017-04-25
EP1912973A2 (en) 2008-04-23
NI200800017A (es) 2009-03-03
EP2284168A3 (en) 2011-04-13
IL188189A0 (en) 2008-03-20
ES2386974T3 (es) 2012-09-10
CN102358736A (zh) 2012-02-22
DK2284167T3 (en) 2017-05-01
TWI406661B (zh) 2013-09-01
CA2614334C (en) 2015-04-21
BRPI0613615A2 (pt) 2011-01-18
EP1912973B1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
IL214659A0 (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
IL187787A0 (en) Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP1948193A4 (en) AMINOPYRIMIDINES SUITABLE AS KINASEINHIBITORS
ATE521238T1 (de) Kristalline modifikationen des pyraclostrobins
EP1921052A4 (en) SEMICONDUCTOR CERAMIC COMPOSITION
IL183380A0 (en) Crystalline forms of linezolid intermediate
HK1121760A1 (en) Novel n-(fluoro-pyrazinyl)-phenylsulfonamides as moodulators of chemokine receptor ccr4.
DE502006007792D1 (de) Temperaturkompensation bei endstufen
ZA200710799B (en) Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
ZA200710457B (en) Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoro-methyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
DE602006005524D1 (de) dingskompensation
ZA200804599B (en) Aminopyrimidines useful as kinase inhibitors
ZA200800245B (en) JNK inhibitors for the treatment of endometriosis
GB0526357D0 (en) Porous silicon composition